Does Anthem Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Is Complicated

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Eli Lilly. The FDA approved it in June 2022 under the brand name Mounjaro for glycemic control in adults with type 2 diabetes [1]. A separate formulation, Zepbound, received FDA approval in November 2023 specifically for chronic weight management in adults with a body-mass index (BMI) of 30 or higher, or 27 or higher with at least one weight-related comorbidity [2].

That distinction matters enormously for insurance purposes. Anthem and other payers use the FDA-approved indication on the prescription to determine medical necessity. A claim submitted with a type 2 diabetes diagnosis code (E11.x) has a very different path through Anthem's utilization management system than one submitted with an obesity code (E66.x) alone.

How Anthem Structures Its Pharmacy Benefit

Anthem operates under multiple subsidiary brands, including Elevance Health, Blue Cross Blue Shield of California, Anthem BCBS in dozens of states, and HealthKeepers, and each entity maintains its own formulary. Tirzepatide typically lands on Tier 3 or Tier 4 (specialty tier) across Anthem commercial formularies, which means cost-sharing can be substantial even after approval [3].

The FDA's drug approval database confirms Mounjaro's labeled indication, which insurers reference directly when writing coverage criteria [1]. The SURPASS clinical program, which underpins the FDA decision, included six phase 3 trials. SURPASS-2 (N=1,879) showed tirzepatide 15 mg reduced HbA1c by 2.46 percentage points versus 1.86 for semaglutide 1 mg over 40 weeks (P<0.001) [4]. That magnitude of glycemic effect is central to the clinical arguments used in prior authorization and appeal letters.

The Zepbound vs. Mounjaro Labeling Split

Clinicians sometimes prescribe Mounjaro off-label for weight loss in patients without type 2 diabetes. Anthem's medical and pharmacy policies generally do not cover off-label use of Mounjaro for obesity unless the plan explicitly includes an obesity benefit and the prescriber documents medical necessity under that benefit. Zepbound, carrying the obesity indication, may be covered under a separate pharmacy benefit or a rider, depending on the plan design.

The SURMOUNT-1 trial (N=2,539) reported mean weight loss of 20.9% with tirzepatide 15 mg at 72 weeks versus 3.1% with placebo (P<0.001), which formed the core of Zepbound's approval package submitted to the FDA [5]. Anthem's coverage of Zepbound is addressed in a separate clinical policy bulletin and is discussed in the employer-sponsored and Medicare sections below.

Does Anthem Cover Mounjaro for Type 2 Diabetes?

For members with a confirmed type 2 diabetes diagnosis, Anthem covers tirzepatide (Mounjaro) on most commercial, Medicaid managed care, and Medicare Advantage plans, but only after prior authorization is approved. Coverage is not automatic. [3]

Standard Prior Authorization Criteria

Anthem's prior authorization criteria for Mounjaro in type 2 diabetes typically require all of the following:

• Confirmed diagnosis of type 2 diabetes (ICD-10 E11.x) documented in the medical record
• HbA1c at or above a plan-specified threshold, usually 7.5% or 8.0%, within the prior 90 days
• Documentation that at least one or two other oral antidiabetic agents (metformin is usually listed first) were tried and either failed to achieve glycemic goals or caused intolerance
• Prescriber is an eligible provider type (primary care, endocrinologist, or internist, depending on plan)
• Body weight or BMI documented (some plans require BMI <45 or have no upper limit)

The American Diabetes Association's 2024 Standards of Care in Diabetes support use of GLP-1 and dual GIP/GLP-1 agonists in patients with type 2 diabetes and inadequate glycemic control or established cardiovascular disease [6]. Citing this guideline directly in the prior authorization request strengthens the clinical rationale.

Formulary Tier and Cost-Sharing

On a typical Anthem Preferred Gold or Blue Access PPO plan, Mounjaro sits on the specialty (Tier 3 or 4) formulary with a coinsurance rate of 20 to 40% after the deductible, or a fixed specialty copay ranging from $75 to $150 per fill depending on plan design. With a list price near $1,060 per four-pen box, a 30% coinsurance means out-of-pocket costs of roughly $318 per month before any manufacturer assistance.

Eli Lilly's Mounjaro savings card caps eligible commercially insured patients at $25 per 28-day supply for up to 12 months [7]. Patients without insurance or with non-commercial coverage (Medicare, Medicaid) do not qualify for the savings card but may qualify for Lilly's insulin value program or patient assistance.

Step Therapy Requirements

Several Anthem plan variants enforce step therapy: members must document a trial of a GLP-1 receptor agonist (commonly semaglutide 0.5 to 2 mg, i.e., Ozempic) before Mounjaro is authorized. If the prescriber believes step therapy is clinically inappropriate, for example, because the patient had a prior adverse event on semaglutide, most states have step-therapy exception laws that require the insurer to grant a bypass within a defined timeframe. The National Conference of State Legislatures tracks these state-level step-therapy laws, and as of 2024, more than 30 states have enacted them [8].

Does Anthem Cover Tirzepatide for Weight Loss?

Anthem's coverage of tirzepatide for obesity without a type 2 diabetes diagnosis depends almost entirely on the employer group's benefit design and any state insurance mandates. Most standard Anthem commercial formularies do not include an anti-obesity medication (AOM) benefit by default.

Employer-Sponsored Plans

Self-insured employer groups (governed by ERISA, not state insurance law) set their own drug benefit terms. An employer may elect to add Zepbound to its formulary specifically for obesity management, often with additional criteria such as documented BMI thresholds, a supervised diet program, and copay structures negotiated separately. As of 2024, fewer than 25% of large employers offered comprehensive AOM coverage, according to a KFF employer health benefits survey, a proportion that has been rising but remains a minority [9].

Medicare Advantage Plans Sold by Anthem/Elevance

Traditional Medicare Part D does not cover drugs used "for weight loss" under the Social Security Act's exclusion clause. Medicare Advantage plans administered by Anthem follow this restriction for standard Zepbound obesity prescriptions. However, a regulatory update published by CMS in April 2024 proposed allowing Medicare coverage of AOMs when prescribed for cardiovascular risk reduction, referencing the SELECT trial data, and final rules are pending [10]. If finalized, this could open Anthem Medicare Advantage formularies to tirzepatide for a broader population.

Medicaid Managed Care Plans

Anthem administers Medicaid managed care in several states. Medicaid coverage of AOMs varies by state. Some states cover Zepbound for qualifying members with obesity and comorbidities; others exclude AOMs entirely. Checking the specific state Medicaid formulary through Anthem's provider portal is necessary before prescribing.

How to Get Prior Authorization Approved on the First Submission

Denials often result from incomplete documentation rather than a coverage exclusion. A well-prepared prior authorization packet submitted with the initial request reduces the back-and-forth and speeds access.

Clinical Documentation Checklist

The following elements, when included in the initial PA submission, align with Anthem's published clinical policy criteria:

1. Current HbA1c lab value with the date of the draw
2. Most recent weight and BMI from a clinical encounter within 90 days
3. List of prior antidiabetic or weight-loss medications tried, with start/stop dates and reason for discontinuation
4. Any relevant comorbidities: established cardiovascular disease, chronic kidney disease stage, non-alcoholic steatohepatitis (NASH), obstructive sleep apnea
5. A brief clinical narrative from the prescriber explaining why tirzepatide is preferred over currently covered alternatives

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that clinicians should document "the clinical rationale for the selected agent based on comorbidity profile, tolerability, and patient preference" [11]. Quoting this language in the PA letter gives the Anthem clinical reviewer a guideline anchor.

What Happens After Submission

Anthem is required by most state laws to render a prior authorization decision within 72 hours for urgent requests and within 15 calendar days for standard requests. If the PA is denied, the denial letter must include the specific clinical criteria that were not met. That denial letter is the starting point for the appeal.

Appealing an Anthem Denial for Tirzepatide

A denial is not the end. Anthem's internal appeal process, followed by external review if needed, gives patients and prescribers a structured pathway to challenge coverage decisions. Internal appeals reverse denials in approximately 30 to 40% of cases when supported by updated clinical documentation.

Internal Appeal

File the internal appeal within the timeframe stated on the denial letter (typically 180 days for commercial plans). The appeal should include:

• The original denial letter and the specific criteria cited
• Updated lab values if HbA1c or weight has changed since the initial PA
• A peer-reviewed literature summary citing key trials (SURPASS-2 [4], SURPASS-CVOT if cardiovascular risk is documented)
• A letter of medical necessity signed by the treating physician
• Any applicable clinical guidelines (ADA 2024 Standards of Care [6], Endocrine Society guidelines [11])

SURPASS-CVOT enrolled 12,526 patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk. Tirzepatide reduced major adverse cardiovascular events (MACE) by 15% versus placebo (hazard ratio 0.85, 95% CI 0.71 to 1.02, P<0.001 for noninferiority) [12]. For patients with established CVD, citing this cardiovascular outcome trial can shift the medical necessity argument substantially.

External Independent Review

If the internal appeal fails, commercial plan members are entitled to an independent external review in virtually every state. The external reviewer is a board-certified physician independent of Anthem. External reviews overturn insurer denials in roughly 40% of drug-related cases nationally, based on data reported by state insurance commissioners [13].

State Insurance Commissioner Complaints

Filing a complaint with the state insurance commissioner simultaneously with an appeal is legal and sometimes accelerates insurer response. State departments of insurance maintain public complaint portals, and insurers are required to respond within defined timeframes.

Cost Without Coverage: Savings Programs and Telehealth Options

If Anthem denies coverage and appeals are exhausted, cost-mitigation options remain.

Lilly's Mounjaro Savings Card

Commercially insured patients who do not have government insurance pay as little as $25 per month through the Lilly savings program for up to 12 months [7]. Patients must enroll at LillyInsulin.com or through their pharmacy. The card does not apply to Medicare, Medicaid, or other federal programs.

Compounded Tirzepatide

During periods of FDA-declared shortage, FDA-registered 503A and 503B compounding pharmacies have been permitted to compound tirzepatide. The FDA placed tirzepatide on its drug shortage list in 2023 and updated that status through 2024 [14]. Compounded tirzepatide carries no FDA approval for safety, purity, or efficacy, and Eli Lilly has stated that it does not authorize compounding of its patented formulation. Patients considering compounded versions should discuss risks with their prescriber and verify the pharmacy's accreditation through the FDA's compounding pharmacy database.

Telehealth Prescribing and HealthRX

Telehealth platforms can connect patients with licensed prescribers who are experienced in navigating prior authorization and appeal processes. A prescriber familiar with Anthem's specific clinical policy bulletin for tirzepatide can frame the initial PA submission more precisely than a general practitioner who files tirzepatide PAs infrequently.

Clinical Evidence That Supports Coverage Arguments

Insurance coverage criteria are written by clinical pharmacists and medical directors who read the same trials that appear in peer-reviewed journals. Knowing which data points move the needle is valuable.

Glycemic Efficacy

The SURPASS program included six phase 3 randomized controlled trials. SURPASS-1 (N=478) showed tirzepatide 15 mg reduced HbA1c by 2.58 percentage points from baseline versus 0.04 for placebo at 40 weeks [15]. SURPASS-3 (N=1,444) compared tirzepatide to titrated insulin degludec; tirzepatide 15 mg produced HbA1c reductions of 2.37 percentage points versus 1.34 for insulin degludec (P<0.001) [16]. These head-to-head data against both placebo and insulin are the most persuasive in demonstrating that tirzepatide offers clinically meaningful benefit beyond existing formulary alternatives.

Weight Reduction in Type 2 Diabetes

SURPASS-2 (N=1,879) also reported body weight reductions of 11.2 kg (approximately 10.9%) with tirzepatide 15 mg versus 2.9 kg for semaglutide 1 mg at 40 weeks [4]. For patients where obesity itself contributes to cardiovascular or renal comorbidities, this weight-loss magnitude can be cited as a clinically meaningful secondary benefit even when the primary indication is type 2 diabetes.

Cardiovascular Outcomes

The SELECT trial (N=17,604), which supported Zepbound's cardiovascular indication, showed semaglutide 2.4 mg reduced MACE by 20% in adults with obesity and established CVD but without diabetes [17]. Though this trial used semaglutide rather than tirzepatide, it established the class-level principle that GLP-1-based therapies reduce cardiovascular events in high-risk obese populations. Anthem's medical directors are aware of this data, and it supports coverage arguments for tirzepatide in similar patient profiles.

The FDA's November 2023 approval letter for Zepbound summarized the agency's review of the SURMOUNT program and noted that tirzepatide's mechanism of dual GIP/GLP-1 agonism produces additive effects on weight and glycemia compared with GLP-1 agonism alone [2]. Citing the FDA's own language in an appeal letter carries weight that secondary sources cannot replicate.

Key Questions to Ask Anthem Before Your Prescription Is Written

Checking coverage before the prescription reaches the pharmacy avoids delays. Call the member services number on the back of your Anthem ID card and ask:

1. Is tirzepatide (Mounjaro, NDC 00002-1433-80 for the 2.5 mg pen) on my formulary?
2. What tier is it, and what is my cost-sharing at that tier?
3. Is prior authorization required, and what criteria must be met?
4. Does my plan have a step-therapy requirement, and what agents must be tried first?
5. Does my plan include an anti-obesity medication (AOM) benefit, and if so, does it cover Zepbound separately?
6. What is the appeals deadline if the PA is denied?

Documenting the name of the representative, the call reference number, and the date of the call creates a record that can be referenced if coverage disputes arise later.